Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 11 | 2023 | 143 | 5.880 |
Why?
|
| Bone Neoplasms | 9 | 2023 | 117 | 4.680 |
Why?
|
| Soft Tissue Neoplasms | 5 | 2022 | 56 | 2.060 |
Why?
|
| Retrospective Studies | 16 | 2023 | 3367 | 1.380 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 186 | 1.170 |
Why?
|
| Margins of Excision | 2 | 2022 | 27 | 0.920 |
Why?
|
| Giant Cell Tumor of Bone | 2 | 2022 | 15 | 0.900 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 80 | 0.900 |
Why?
|
| Chondrosarcoma | 1 | 2023 | 32 | 0.870 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 37 | 0.860 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 66 | 0.840 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 56 | 0.840 |
Why?
|
| Neutrophils | 1 | 2023 | 96 | 0.830 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 11 | 0.790 |
Why?
|
| Prognosis | 7 | 2023 | 758 | 0.750 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 9 | 0.740 |
Why?
|
| Myxosarcoma | 1 | 2020 | 3 | 0.730 |
Why?
|
| Osteosarcoma | 1 | 2021 | 35 | 0.730 |
Why?
|
| Fibrosarcoma | 1 | 2020 | 9 | 0.730 |
Why?
|
| Humans | 22 | 2023 | 26286 | 0.720 |
Why?
|
| Prosthesis-Related Infections | 1 | 2022 | 184 | 0.670 |
Why?
|
| Osteoarthritis | 1 | 2022 | 316 | 0.600 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2022 | 790 | 0.580 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2022 | 615 | 0.500 |
Why?
|
| Treatment Outcome | 6 | 2023 | 3391 | 0.480 |
Why?
|
| Child | 4 | 2021 | 1236 | 0.450 |
Why?
|
| Survival Rate | 4 | 2021 | 322 | 0.430 |
Why?
|
| Limb Salvage | 2 | 2023 | 12 | 0.420 |
Why?
|
| Neoadjuvant Therapy | 3 | 2022 | 63 | 0.400 |
Why?
|
| Adolescent | 4 | 2021 | 2080 | 0.400 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 27 | 0.390 |
Why?
|
| Young Adult | 4 | 2021 | 1886 | 0.390 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 38 | 0.390 |
Why?
|
| Neoplasm Staging | 2 | 2022 | 314 | 0.370 |
Why?
|
| Adult | 6 | 2022 | 7448 | 0.350 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 326 | 0.340 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 1738 | 0.340 |
Why?
|
| Middle Aged | 6 | 2021 | 8601 | 0.280 |
Why?
|
| Prospective Studies | 2 | 2023 | 1668 | 0.280 |
Why?
|
| Curettage | 2 | 2022 | 9 | 0.230 |
Why?
|
| Biopsy | 2 | 2023 | 200 | 0.230 |
Why?
|
| Lower Extremity | 1 | 2023 | 38 | 0.220 |
Why?
|
| Surgical Flaps | 1 | 2023 | 50 | 0.220 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 16 | 0.220 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 17 | 0.220 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 55 | 0.220 |
Why?
|
| Female | 6 | 2021 | 14539 | 0.220 |
Why?
|
| Bone Cements | 2 | 2022 | 88 | 0.220 |
Why?
|
| Male | 6 | 2021 | 14162 | 0.210 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 4675 | 0.210 |
Why?
|
| Lymphocytes | 1 | 2023 | 59 | 0.210 |
Why?
|
| Preoperative Care | 1 | 2023 | 122 | 0.210 |
Why?
|
| Necrosis | 1 | 2022 | 26 | 0.210 |
Why?
|
| Plasma Gases | 1 | 2022 | 2 | 0.210 |
Why?
|
| Replantation | 1 | 2022 | 8 | 0.200 |
Why?
|
| Reoperation | 3 | 2022 | 879 | 0.200 |
Why?
|
| Infant | 2 | 2021 | 520 | 0.200 |
Why?
|
| Child, Preschool | 2 | 2021 | 593 | 0.200 |
Why?
|
| Femur | 2 | 2022 | 383 | 0.200 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 507 | 0.200 |
Why?
|
| Infant, Newborn | 2 | 2021 | 593 | 0.200 |
Why?
|
| Printing, Three-Dimensional | 1 | 2021 | 9 | 0.200 |
Why?
|
| Metastasectomy | 1 | 2021 | 7 | 0.200 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 33 | 0.190 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 49 | 0.190 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 84 | 0.190 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 46 | 0.180 |
Why?
|
| SEER Program | 1 | 2021 | 38 | 0.180 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 21 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 77 | 0.180 |
Why?
|
| Hemipelvectomy | 1 | 2020 | 2 | 0.180 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 4 | 0.180 |
Why?
|
| Aged | 4 | 2021 | 8765 | 0.180 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 159 | 0.180 |
Why?
|
| Ganglion Cysts | 1 | 2020 | 6 | 0.180 |
Why?
|
| Contracture | 1 | 2020 | 13 | 0.180 |
Why?
|
| Allografts | 1 | 2021 | 228 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 339 | 0.170 |
Why?
|
| Elbow Joint | 1 | 2020 | 125 | 0.160 |
Why?
|
| Time Factors | 1 | 2022 | 1391 | 0.150 |
Why?
|
| Hip Prosthesis | 1 | 2022 | 531 | 0.140 |
Why?
|
| Spinal Fusion | 1 | 2020 | 480 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 32 | 0.090 |
Why?
|
| Tibia | 1 | 2010 | 256 | 0.080 |
Why?
|
| Cell Division | 1 | 2022 | 79 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 44 | 0.050 |
Why?
|
| Apoptosis | 1 | 2022 | 195 | 0.050 |
Why?
|
| Pneumonectomy | 1 | 2021 | 67 | 0.050 |
Why?
|
| Lung | 1 | 2021 | 155 | 0.050 |
Why?
|
| Joint Capsule Release | 1 | 2020 | 9 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 281 | 0.040 |
Why?
|
| Elbow | 1 | 2020 | 52 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 315 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2022 | 482 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2022 | 506 | 0.040 |
Why?
|
| Risk Factors | 1 | 2022 | 2265 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 1838 | 0.030 |
Why?
|
| Thoracoscopy | 1 | 2010 | 20 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 70 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 338 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 723 | 0.020 |
Why?
|